• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Candocuronium iodide     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatQuaternaryAmmoniumCompounds, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatMolecularFormulasyago:Abstraction100002137yago:Chemical114806838yago:Communication100033020yago:Compound114818238yago:Formula106816935yago:Halide114904359yago:Iodide114922371yago:Material114580897yago:Matter100020827yago:Message106598915yago:MolecularFormula106817173yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:QuaternaryAmmoniumCompound114691231yago:Relation100031921yago:WikicatIodidesdrugyago:Salt115010703yago:Statement106722453yago:Substance100019613yago:WikicatQuaternaryAmmoniumCompounds New Facet based on Instances of this Class

Candocuronium iodide (INN, formerly chandonium, HS-310) is an aminosteroid neuromuscular-blocking drug. Its use in anesthesia for endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation was briefly evaluated in clinical studies in India. However, further development was discontinued due to attendant cardiovascular effects, primarily tachycardia that was about the same as the clinically established pancuronium bromide. Candocuronium demonstrated a short duration and a rapid onset of action, with little or no ganglion blocking activity, with a greater potency than pancuronium.